Abiopharma

Mancini Marianna 🟡 adjusted position in 106.4K shares (1 derivative) of Viking Therapeutics, Inc. (VKTX) at $35.42 ($5.1M) Transaction Date: Jan 02, 2026 | Filing ID: 003115

Lian Brian 🟡 adjusted position in 245.4K shares (1 derivative) of Viking Therapeutics, Inc. (VKTX) at $35.42 ($13.9M) Transaction Date: Jan 02, 2026 | Filing ID: 003113

SINGLETON J MATTHEW 🟢 acquired 23.6K shares (1 derivative) of Viking Therapeutics, Inc. (VKTX) at $35.42 Transaction Date: Jan 02, 2026 | Filing ID: 003112

MACARTNEY LAWSON 🟢 acquired 23.6K shares (1 derivative) of Viking Therapeutics, Inc. (VKTX) at $35.42 Transaction Date: Jan 02, 2026 | Filing ID: 003111

Rowland Charles A Jr 🟢 acquired 23.6K shares (1 derivative) of Viking Therapeutics, Inc. (VKTX) at $35.42 Transaction Date: Jan 02, 2026 | Filing ID: 003110

FOEHR MATTHEW W 🟡 adjusted position in 7.5K shares (2 derivative) of Viking Therapeutics, Inc. (VKTX) at $35.42 ($1.4M) Transaction Date: Jan 02, 2026 | Filing ID: 003109

Rouan Sarah Kathryn 🟢 acquired 23.6K shares (1 derivative) of Viking Therapeutics, Inc. (VKTX) at $35.42 Transaction Date: Jan 02, 2026 | Filing ID: 003108

Smith Jeffrey T L 🟡 adjusted position in 10.5K shares (1 derivative) of Zymeworks Inc. (ZYME) at $25.10 Transaction Date: Jan 05, 2026 | Filing ID: 003102

Galbraith Kenneth 🟡 adjusted position in 54.3K shares (2 derivative) of Zymeworks Inc. (ZYME) at $25.10 ($1.4M) Transaction Date: Jan 05, 2026 | Filing ID: 003097

Moore Paul Andrew 🟡 adjusted position in 20.1K shares (2 derivative) of Zymeworks Inc. (ZYME) at $25.10 Transaction Date: Jan 05, 2026 | Filing ID: 003095

New Form 144/A - ARROWHEAD PHARMACEUTICALS, INC. Filed: 2026-01-05 AccNo: 0001628280-26-000759 Size: 6 KB

Steinhart Richard I 🟢 acquired 70.0K shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) Transaction Date: Jan 01, 2026 | Filing ID: 000837

Director Mehta Vimal 🟢 acquired 199.0K shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) Transaction Date: Jan 01, 2026 | Filing ID: 000835

Rodriguez Javier 🟢 acquired 70.0K shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) Transaction Date: Jan 01, 2026 | Filing ID: 000834

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China